Work

Nivolumab in combination with daratumumab, with or without pomalidomide and dexamethasone, for relapsed/refractory multiple myeloma: 2 cohorts of the phase 1 CheckMate 039 safety study.

Year: 2017

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2017.35.15_suppl.tps3102

Authors: Alexander M. Lesokhin, Shaji Kumar, Mihaela A. Popa McKiver, Lili Zhu, Benedetto Farsaci, Ivan Borrello

Institutions: Memorial Sloan Kettering Cancer Center, Mayo Clinic, Bristol-Myers Squibb (United States), Johns Hopkins University

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2739338574

Cites:

Cited by: 2

Related to: 10